Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATIC: HDM SLIT-tablet in Children
NCT04145219Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Oct 2019
- Primary completion
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of SQ SLIT-tablet in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by ALK-Abelló. Primary endpoint: Total Combined Rhinitis Symptom and Medication Score at 8 weeks. Started Oct 2019; status: completed.
02
Drugs
SQ SLIT-tablet
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT04145219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04145219.